Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2022 15:30 ET | Source: SOTIO Biotech

Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting

PRAGUE, Czech Republic and BASEL, Switzerland and CAMBRIDGE, Mass, April 12, 2022 (GLOBE NEWSWIRE) -- Interim Results of the Phase 1 AURELIO-03 study of SOT101 in combination with pembrolizumab...
March 16, 2022 08:00 ET | Source: SOTIO Biotech

SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022

Oral presentation will focus on interim efficacy and safety data from the Phase 1/1b AURELIO-03 study of SOT101 in combination with pembrolizumabPoster presentations will feature preclinical data on...
December 08, 2021 08:00 ET | Source: SOTIO Biotech

SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indicationsThe study will be conducted in the US and selected European countries and will begin in the first...
December 02, 2021 08:00 ET | Source: SOTIO Biotech

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

PPF Group provides funding to advance SOTIO through key clinical milestonesProceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial Three...
November 18, 2021 08:00 ET | Source: SOTIO Biotech

SOTIO Strengthens its Strategic Advisory Board with Esteemed Oncology Experts and Industry Veterans

PRAGUE, Czech Republic, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immune-oncology company owned by PPF Group, announced the addition of three world-renowned clinical oncology...
November 16, 2021 08:00 ET | Source: SOTIO Biotech

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programsRights to LCB’s ADC platform acquired for total of up to $1027.5 million payable based...
November 12, 2021 07:00 ET | Source: SOTIO Biotech

SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors

Majority of patients receiving SOT101 (SO-C101) + pembrolizumab had confirmed clinical benefitClinical responses have been observed in patients progressing on previous anti-PD-1 treatmentSOT101...
November 03, 2021 08:00 ET | Source: Sotio

SOTIO to Present New Data from Phase 1 Study of IL-15 Superagonist, SOT101, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

SOTIO will present three posters discussing data that highlight the encouraging safety and efficacy for SOT101 (SO-C101) as a monotherapy and in combination with pembrolizumab for the treatment of...
June 04, 2021 08:10 ET | Source: Sotio

SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting

PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its...
May 11, 2021 08:41 ET | Source: Sotio

SOTIO to Present Biomarker Data from its SOV01 – DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting

PRAGUE, Czech Republic, May 11, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO...